Cover Image
市場調查報告書

細菌性陰道炎:開發平台分析

Bacterial Vaginosis - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 245975
出版日期 內容資訊 英文 47 Pages
訂單完成後即時交付
價格
Back to Top
細菌性陰道炎:開發平台分析 Bacterial Vaginosis - Pipeline Review, H1 2017
出版日期: 2017年02月28日 內容資訊: 英文 47 Pages
簡介

細菌性陰道炎(BV)是由於陰道內細菌異常增生而發病的發炎性疾病的一種。主要的症狀有陰道內部發癢,及排尿時燒灼感,陰道分泌物的水分增加·稀薄化等。主要的治療藥有抗生素等。

本報告提供全球各國治療細菌性陰道炎所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

細菌性陰道炎概要

治療藥的開發

  • 細菌性陰道炎開發中產品:概要
  • 細菌性陰道炎開發中產品:比較分析

企業開發中的治療藥

大學/機關研究中的治療藥

開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

企業開發中的產品

大學/機關研究中的產品

治療藥的開發企業

  • Alfa Wassermann S.p.A
  • AmVac AG
  • Osel Inc.
  • Starpharma Holdings Limited
  • Symbiomix Therapeutics, LLC

治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • AMV-100
  • astodrimer
  • benzoyl peroxide
  • LACTIN-V
  • Peptide for Bacterial Vaginosis
  • rifaximin
  • secnidazole

最新開發平台趨勢

暫停中的計劃

開發中止的產品

產品開發的里程碑

  • 主要消息和新聞稿
  • ■附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8986IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bacterial Vaginosis - Pipeline Review, H1 2017, provides an overview of the Bacterial Vaginosis (Infectious Disease) pipeline landscape.

Bacterial vaginosis (BV), also known as vaginal bacteriosis is a type of vaginal inflammation caused by overgrowth of bacteria present in vagina. Symptoms include vaginal itching; burning during urination and vaginal discharge may become watery and thin. Treatment includes antibiotics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Bacterial Vaginosis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Bacterial Vaginosis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bacterial Vaginosis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Bacterial Vaginosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I and Preclinical stages are 2, 2, 1 and 2 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Bacterial Vaginosis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Bacterial Vaginosis (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Bacterial Vaginosis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Bacterial Vaginosis (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Bacterial Vaginosis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Bacterial Vaginosis (Infectious Disease)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Bacterial Vaginosis (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Bacterial Vaginosis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Bacterial Vaginosis - Overview
  • Bacterial Vaginosis - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Bacterial Vaginosis - Therapeutics Assessment
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Bacterial Vaginosis - Companies Involved in Therapeutics Development
    • Evofem Inc
    • Osel Inc
    • Starpharma Holdings Ltd
    • Symbiomix Therapeutics LLC
  • Bacterial Vaginosis - Drug Profiles
    • Amphora - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • astodrimer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • benzoyl peroxide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LACTIN-V - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • secnidazole - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule for Bacterial Vaginosis and Candidiasis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • subtilosin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TOL-463 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Bacterial Vaginosis - Dormant Projects
  • Bacterial Vaginosis - Discontinued Products
  • Bacterial Vaginosis - Product Development Milestones
    • Featured News & Press Releases
      • Jan 19, 2017: Symbiomix Therapeutics Submits New Drug Application to US FDA for Solosec for the Treatment of BV
      • Jan 12, 2017: VivaGel BV granted QIDP and Fast Track designation by US FDA
      • Nov 07, 2016: Symbiomix Therapeutics to Present Data on Solosec (Secnidazole) Oral Granules at 2016 AAPS Annual Meeting and Exposition
      • Oct 25, 2016: Symbiomix Therapeutics Data Presented on Clinician/Patient Perspectives of Bacterial Vaginosis at International Society for Quality of Life Research 23rd Annual Conference
      • Oct 13, 2016: Enrolment complete for Phase 3 VivaGel BV-R program
      • Aug 17, 2016: Evofem Announces First Patient Enrolled in a Clinical Trial to Determine the Effect and Duration of Amphora Gel on Vaginal pH
      • Aug 17, 2016: Symbiomix Therapeutics Accelerates Commercial Launch Preparation for Solosec Following Presentation of Results from Second Pivotal Trial at IDSOG
      • Jul 21, 2016: Osel Comments on New Study Showing Role of Vaginal Microbiome in Women Health
      • May 26, 2016: Symbiomix Therapeutics Announces Positive Results from Phase 3 Trial of SYM-1219 for Bacterial Vaginosis, and Pre-NDA Meeting with FDA Supportive of 2016 NDA Filing
      • May 11, 2016: Osel Lead Product LACTIN-V Enters Phase 2b Study to Prevent Recurrence of Bacterial Vaginosis
      • Mar 31, 2016: Evofem Files IND for Evaluation of Prevention of Recurrence of Bacterial Vaginosis
      • Jan 11, 2016: Evofem Holdings Announces Successful Completion of Pre-IND Meeting for Amphora
      • Oct 14, 2015: Additional US Patent granted for VivaGel BV
      • Sep 24, 2015: EU Marketing Approval Granted for VivaGel BV
      • Sep 21, 2015: Symbiomix Therapeutics Presents Data at ICAAC/ICC Demonstrating Oral Pharmacokinetics of Lead Product SYM-1219 Administered With and Without Food
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Bacterial Vaginosis, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Bacterial Vaginosis - Pipeline by Evofem Inc, H1 2017
  • Bacterial Vaginosis - Pipeline by Osel Inc, H1 2017
  • Bacterial Vaginosis - Pipeline by Starpharma Holdings Ltd, H1 2017
  • Bacterial Vaginosis - Pipeline by Symbiomix Therapeutics LLC, H1 2017
  • Bacterial Vaginosis - Dormant Projects, H1 2017
  • Bacterial Vaginosis - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Bacterial Vaginosis, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top